Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Medication Adherence’s Impact on Outcomes in MM

Clin Lymphoma Myeloma Leuk; ePub 2018 Feb 3; Gupta, et al

People with multiple myeloma are prone to experience significant workplace and functional impairment, high out of pocket costs, and frequent office visits, researchers concluded after conducting a cross-sectional study involving 162 individuals. Adherence to therapy can blunt the impact. Participants with multiple myeloma were divided into 2 groups according to their medication adherence scores. They completed 3 surveys, including the Functional Assessment of Cancer Therapy–Multiple Myeloma (FACT-MM): Among the results:

  • FACT-MM scores averaged 98.5.
  • Absenteeism and presenteeism averaged 18% and 52%, respectively.
  • Work productivity and activity impairment averaged 57% and 50%, respectively.
  • Out-of-pocket costs averaged ~$700 in the prior 3 months.
  • Patients spent an average of ~7 hours in monthly appointments with clinicians.
  • Patients with high medication adherence had higher FACT-MM scores.
  • Those with lower medication adherence reported greater activity impairment and were more apt to be overwhelmed/frustrated with appointment rescheduling.
Citation:

Gupta S, Abouzaid S, Liebert R, Parikh K, Ung B, Rosenberg A. Assessing the effect of adherence on patient-reported outcomes and out of pocket costs among patients with multiple myeloma. [Published online ahead of print February 3, 2018]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2018.01.006.

This Week's Must Reads

Undertreatment of Newly-Diagnosed MM Evaluated, Clin Lymphoma Myeloma Leuk; ePub 2018 Feb 3; Fakhri, et al

Blacks Fare Better After This Type of Transplant , Biol Blood Marrow Transplant.; ePub 2018 Jan 25; Solomon, et al

Aminocaproic Acid, Bleeding Complications Assessed, Leuk Lymphoma; ePub 2018 Feb 9; Juhl, Roddy, et al

Medication Adherence’s Impact on Outcomes in MM , Clin Lymphoma Myeloma Leuk; ePub 2018 Feb 3; Gupta, et al

FDA Approves Rebinyn to Treat Hemophilia B, Novo Nordisk news release; 2018 Feb 8